HomeCompareONCS vs ABBV

ONCS vs ABBV: Dividend Comparison 2026

ONCS yields 721.50% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ONCS wins by $1167526.90M in total portfolio value
10 years
ONCS
ONCS
● Live price
721.50%
Share price
$0.28
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1167527.00M
Annual income
$917,400,379,323.42
Full ONCS calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ONCS vs ABBV

📍 ONCS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodONCSABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ONCS + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ONCS pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ONCS
Annual income on $10K today (after 15% tax)
$61,327.56/yr
After 10yr DRIP, annual income (after tax)
$779,790,322,424.91/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ONCS beats the other by $779,790,301,368.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ONCS + ABBV for your $10,000?

ONCS: 50%ABBV: 50%
100% ABBV50/50100% ONCS
Portfolio after 10yr
$583763.55M
Annual income
$458,700,202,047.59/yr
Blended yield
78.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ONCS
Analyst Ratings
1
Buy
2
Hold
Consensus: Hold
Altman Z
-59.8
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ONCS buys
0
ABBV buys
0
No recent congressional trades found for ONCS or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricONCSABBV
Forward yield721.50%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$1167527.00M$102.3K
Annual income after 10y$917,400,379,323.42$24,771.77
Total dividends collected$1147386.89M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: ONCS vs ABBV ($10,000, DRIP)

YearONCS PortfolioONCS Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$82,850$72,150.07$11,550$430.00+$71.3KONCS
2$647,307$558,657.82$13,472$627.96+$633.8KONCS
3$4,771,864$4,079,244.95$15,906$926.08+$4.76MONCS
4$33,210,240$28,104,345.93$19,071$1,382.55+$33.19MONCS
5$218,333,899$182,798,941.49$23,302$2,095.81+$218.31MONCS
6$1,356,770,606$1,123,153,334.78$29,150$3,237.93+$1356.74MONCS
7$7,974,641,684$6,522,897,135.54$37,536$5,121.41+$7974.60MONCS
8$44,364,079,088$35,831,212,485.47$50,079$8,338.38+$44364.03MONCS
9$233,763,200,588$186,293,635,964.16$69,753$14,065.80+$233763.13MONCS
10$1,167,527,003,952$917,400,379,323.42$102,337$24,771.77+$1167526.90MONCS

ONCS vs ABBV: Complete Analysis 2026

ONCSStock

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinical trials collaboration and supply agreement (KEYNOTE-695) and metastatic triple negative breast cancer, which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and technology to treat liver, lung, bladder, pancreatic, and other visceral lesions. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. The company was incorporated in 2008 and is headquartered in Pennington, New Jersey.

Full ONCS Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ONCS vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ONCS vs SCHDONCS vs JEPIONCS vs OONCS vs KOONCS vs MAINONCS vs JNJONCS vs MRKONCS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.